EGFR and non-small cell lung carcinoma: We also evaluated the use ABT-737 in erlotinib-resistant cells, as we previously showed that ABT-737 and erlotinib resensitized NSCLC cells expressing EGFR-mutant with the BIM deletion polymorphism, leading to erlotinib-induced cell apoptosis.